Compare Agilent Technologies Inc (A) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Charles Schwab Corporation Common Stock — how do they compare? Agilent Technologies Inc trades at $129.02 (market cap $37.04B), while Charles Schwab Corporation Common Stock trades at $102.34 (market cap $177.27B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 4.8× Agilent Technologies Inc's market cap, and Charles Schwab Corporation Common Stock pays the higher dividend (1.26%). Which is the better fit depends on your goals.
| A | SCHW | |
|---|---|---|
Market Cap | $37.04B | $177.27B |
Sector | Health | Financials |
52-Week High | $157.20 | $107.21 |
52-Week Low | $110.24 | $85.35 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Charles Schwab (SCHW) trades at $101.93, up 5.08% with strong technical momentum and bullish moving averages. The stock shows robust fundamentals with a 37.99% net income margin and consistent earnings beats, including Q1 2026 EPS of $1.43 exceeding expectations. Recent news highlights retail trading growth and a new prediction market venture with Cboe, supporting positive sentiment.
Outlook remains favorable with a $120.38 analyst price target implying 18% upside, though overbought RSI signals near-term caution. Key risks include interest rate sensitivity and competitive pressures. Wall Street consensus is bullish with 58% buy ratings, reflecting confidence in Schwab's revenue diversification and asset growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
